Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

National COVID-19 Guidelines

Drugline Volume 392

The coronavirus disease (COVID-19) pandemic is presenting a range of challenges to healthcare professionals. One of the biggest issues in any rapidly evolving space is the ability to access current and reliable information. A…

Read more

Prescribing Restrictions for Hydroxychloroquine

Drugline Volume 391

The Therapeutic Goods Administration (TGA) has issued an alert advising of new prescribing restrictions for hydroxychloroquine. These restrictions have been introduced following reports of increased off-label prescribing for the management of coronavirus disease (COVID-19),…

Read more

Update on Influenza Vaccines

Drugline Volume 390

The Australian Technical Advisory Group on Immunisation (ATAGI) has released its advice for the administration of seasonal influenza vaccines in 2020. Influenza vaccines used in Australia this year will be quadrivalent and comprise two…

Read more

Generic Tiotropium Capsules

Drugline Volume 389

A generic tiotropium capsule has recently been added to the Pharmaceutical Benefits Scheme (PBS). Braltus® capsules are considered equivalent to Spiriva® capsules for the purposes of brand substitution on the PBS. However, some important…

Read more

Non-Steroidal Topical Therapy for Dermatitis

Drugline Volume 388

Topical corticosteroids have long been the mainstay of treatment for dermatitis that does not respond to moisturisers and emollients. Crisaborole is a new non-steroidal option approved for use in mild to moderate atopic dermatitis…

Read more

Updated PBS-listing for Pembrolizumab in treatment of metastatic non-small cell lung cancer

Drugline Volume 387

Pembrolizumab is now available on the Pharmaceutical Benefits Scheme (PBS) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) irrespective of programmed death ligand-1 (PD-L1) status. In the KEYNOTE-189 trial, pembrolizumab was used in…

Read more
Load More